HC Wainwright & Co. Reiterates Buy on Can Fite Biofarma, Maintains $18 Price Target
HC Wainwright & Co. analyst Vernon Bernardino reiterates Can Fite Biofarma (AMEX:CANF) with a Buy and maintains $18 price target.
Can Fite Biofarma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 759.85% HC Wainwright & Co. → $18 Reiterates Buy → Buy 10/24/2023 759.85% HC Wainwright & Co. $
Buy Rating Affirmed for Can-Fite BioPharma on IND Clearance and Positive Clinical Study Outlook
Express News | The FDA Has Granted Investigational New Drug Clearance For Can-Fite Biopharma's Namodenoson, For Metabolic Dysfunction-Associated Steatohepatitis, Also Known As Non-alcoholic Steatohepatitis, For The Company's Ongoing Phase 2B Study
Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces that the U.S. Food
Can-Fite BioPharma Advances ED Treatment Patent
Can-Fite Received Notice of Allowance From the European Patent Office for the Treatment of Erectile Dysfunction With CF602
Patent has already been issued in other major markets including the U.S. Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersProcessa Pharma (NASDAQ:PCSA) shares moved upwards by 31.2% to $2.12 during Thursday's pre-market session. The company's market cap stands at $6.0 million. Cyclacel Pharmaceuticals (NASDAQ:CYCC
Express News | Can-Fite Biopharma Announced It Published An Article In The Experimental And Therapeutic Medicine Journal, "Long-term Complete Response To Namodenoson In Liver Cancer With Child-Pugh B Cirrhosis
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
A pivotal Phase III trial for advanced liver cancer, approved by FDA & EMA and a MASH Phase IIb are enrolling patients Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline
Can-Fite: Submits FDA With an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
Namodenoson demonstrated anti-fibrosis, anti-steatosis and anti-inflammatory effects in former Phase IIa study Patient enrolment for Phase IIb study is ongoing in Europe and Israel Can-Fite BioPharma Ltd.
Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV
US Investors Beware: Tax Complications for Can-Fite BioPharma Shareholders
Can-Fite BioPharma Reports Reduced Losses in 2023
Can Fite Biofarma: Q4 Earnings Insights
Can Fite Biofarma (AMEX:CANF) reported its Q4 earnings results on Thursday, March 28, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsCan Fite Biofarma beat estimate
Express News | Can Fite Biofarma FY GAAP EPS $(0.01), Same YoY, Sales $743.00K Down From $810.00K YoY
Can-Fite Biopharma GAAP EPS of -$0.01, Revenue of $0.74M
Namodenoson Treatment for Pancreatic and Liver Cancer: Data Will Be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology and inflammatory diseases, today announced its VP of Business Development, Dr. Sari Fishman, will present data from the pancreatic and liver cancer programs during numerous partnering meetings at the BIO-Europe Spring 2024 in Barcelona, Spain, on Mar 18-27, 2024
Express News | Can-Fite BioPharma Announced Notice Of Allowance In Canada For Its Patent Application Regarding Se Of Namodenoson For The Reduction Of Liver Fat In Patients With NASH
Buy Rating Affirmed for Can-Fite BioPharma Amidst Strategic Expansions and Positive Clinical Prospects
No Data